Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.
Viral N ShahAmer Al-KaradshehCathy BarnesJose MandrySamer NakhleKarin Wernicke-PantenDaniel KramerWolfgang SchmiderSuzanne PierreLenore TeichertBaerbel RotthaeuserBhaswati MukherjeeTimothy S BaileyPublished in: Diabetes, obesity & metabolism (2023)
PK exposure of SAR-Asp (switching group) and reference NN-Asp (non-switching group) were similar, supporting interchangeability between these two insulin aspart products.